BN_（52021）对血小板活化因子引起的银屑病患者中性白细胞聚集反应的影响

Effect of BN52021 on platelet activating factor induceilaggregation of psoriatic polymorphonuclear neutrophiis

采用聚集仪测定了血小板活化因子（ＰＡＦ）拮抗剂ＢＮ５２０２１对ＰＡＦ引起银屑病患者嗜中性白细胞（ＰＭＮ）聚集反应的影响。结果表明，ＰＡＦ对ＰＭＮ有较强的聚集作用，并呈剂量依赖关系；银屑病患者ＰＭＮ对低浓度ＰＡＦｆ＜１０（－８）ｍｏｌ／Ｌ）聚集反应明显高于正常人（ｐ＜０．０５），而对高浓度ＰＡＦ（＞１０（－７）ｍｏｌ／Ｌ）聚集反应则与正常人差异无显著意义（Ｐ＞０．０５）。ＢＮ５２０２１能明显抑制ＰＡＦ对ＰＭＮ的聚集作用，呈时间和剂量效应关系，对患者及正常人ＩＣ５０分别为１３×１０（－６）ｍｏｌ／Ｌ及１２×１０（－６）ｍｏｌ／Ｌ。提示ＰＡＦ与ＰＭＮ在银屑病皮损炎症过程起重要病理生理作用，ＰＡＦ拮抗剂有可能成为银屑病治疗有效新途径。

e investigated the aggregation of PMN from 20psoriasis patients (PP) and 12 health persons (HP) toPAF and the effect of PAF antagonist BN 52021 onthe aggregation. PAF induced a dose dependentaggregative response of polymopohonuclearneutrophils (PMN) from PP and HP. The aggregativeresponses of PMN from PP to lower concentrations ofPAF were increased (P<0.05) and to higher coneen-trations of PAF were not different to that of PMNfrom HP BN 52021 could time- and dose-dependently inhibit the aggregation of PMN from PPand HP to PAF, and their IC50 was 1 .3 ×10(-6)mol and1.2×10(-6)mol respectively. It is suggested that PAFand PMN play an important pathophy- siologicalrole in the development of psoriasis, and applicationof PAF antagonists may be a new and effective ap-proach to the management of psoriasis.